Description: Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. Betta Pharmaceuticals Co., Ltd. was founded in 2003 and is headquartered in Hangzhou, China.
Home Page: www.bettapharma.com
No. 355, Xingzhong Road
Hangzhou,
China
Phone:
86 571 8613 0357
Officers
| Name | Title |
|---|---|
| Mr. Lieming Ding | Founder, Chairman of Directors, CEO & GM |
| Mr. Fan Jianxun | VP & Chief Financial Officer |
| Mr. Jiang Wan | Sr. VP, Chief Operations Officer & Non Independent Director |
| Mr. Jiabing Wang | Sr. VP, Chief Scientific Officer & Non Independent Director |
| Mr. Lingxi Wu | Independent Director and Board Sec. |
| Dr. Yinxiang Wang | Pres |
| Dr. Xinshan Kang | Chief Scientist in Drug Discovery |
| Mr. Wanyu Cai | Sr. VP |
| Mr. Hao Wu | Sr. Director, Head of Hangzhou R&D Center and Supervisor |
| Mr. Wenxin Xu | Sr. Director & Head of Immunology |
Exchange: SHE
Country: CN : China
Currency: Renminbi (¥)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 183.8182 |
| Price-to-Book MRQ: | 4.3194 |
| Price-to-Sales TTM: | 9.6776 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1677 |